Approval · Notice of Compliance 623 · 2002
IFEX: Notice of Compliance 623
Issued February 4, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 623
- Date
- February 4, 2002
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antineoplastic agent
Products in this notice
Medicinal ingredients
- IFOSFAMIDE 3 G per VIAL
- IFOSFAMIDE 1 G per VIAL